Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
about
Screening for cervical cancer: when theory meets realityAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerCervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choicesHuman papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspectiveA systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screeningAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.New strategies for human papillomavirus-based cervical screeningHuman papillomavirus and cervical cancer: biomarkers for improved prevention effortsClinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) studyA cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese womenPerformance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study.Human papillomavirus infection and anxiety: analyses in women with low-grade cervical cytological abnormalities unaware of their infection status.Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening.Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study.Detection of human papillomaviruses by polymerase chain reaction and ligation reaction on universal microarrayComparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.Randomised health services studies.Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study)HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross-sectional study.Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs.Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.Feasibility of self-sampling and human papillomavirus testing for cervical cancer screening in First Nation women from Northwest Ontario, Canada: a pilot studyRate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programmeThe known unknowns of HPV natural history.HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.Women's intentions to receive cervical cancer screening with primary human papillomavirus testing.The performance of anal cytology as a screening test for anal HSILs in homosexual men.Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval.Perceptions and Experiences of Human Papillomavirus (HPV) Infection and Testing among Low-Income Mexican Women.HPV-DNA testing for cervical cancer precursors: from evidence to clinical practiceAtypical squamous cells of undetermined significance in patients with HPV positive DNA testing and correlation with disease progression by age group: an institutional experience.New insights into cervical cancer screening.Optimizing technology for cervical cancer screening in high-resource settings.Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in FinlandPrimary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL StudyHuman papillomavirus: what every provider should know.Prevention of invasive cervical cancer in the United States: past, present, and future.
P2860
Q21261292-B3DBA49F-B4D9-43ED-B04B-4A558D963598Q24607403-2B7EDFD4-89B6-4B45-B854-5C7B265A2284Q26775085-43CC41B2-2E26-4674-BF23-1429859AA904Q26799791-715FCF81-F785-440B-86FB-6D00B7EAC076Q26824878-A27F1CC8-8DE7-4744-8F58-8A77803F9B11Q26828840-9780BB2F-FA32-4BFD-B3C0-9C7F5211FA16Q26851699-9561B088-58A5-4EE5-B43E-96FB5D70DCE4Q27023127-97AB192C-0C39-4577-8A89-9D526FFFCA9DQ30651813-1D9124BA-2B4C-46B2-A33E-3B6D110DFC45Q33679663-2ACFF828-DD70-456A-8791-8C41054C9BFDQ33746081-160289D7-AA92-464F-A852-8DE3428B50C8Q33834332-28FB0111-E51E-48C3-9398-D9DEEFCBE4E8Q33940861-C0CCAD1E-688B-43EA-A3B0-79BA7C7971FCQ34059732-E8C4FA9B-A60F-4886-A904-945348DB293AQ34141644-2BDCBE88-4C19-43CF-A53A-7179C2AFA142Q34212228-C0E56C93-7EA5-4F6F-89BC-04E5BCD9C1F9Q34250191-82A83B43-B38C-4C07-9300-5DE009D0BC8AQ34264588-2B641A8A-A90A-46BD-8494-2F07ACB1AC4AQ34286142-579884AC-E9CB-4AF7-8B11-68EEA57DBB66Q34485433-E3F7503E-3B02-4786-9745-78837B06906EQ34584632-3970FA30-B274-476A-BEF6-A43FB6865583Q35141881-0826A4FF-32A5-44E9-A210-A853F1B78934Q35203306-8E115DB6-7A27-43FB-A667-7CB773AA7CCCQ35319696-54A8EF1C-85A6-4C68-B813-8163D06DBEE7Q35324720-89966DD7-9BD4-457F-8570-C248067EEECAQ35578583-872D0BC2-E6C5-4DE7-A6B7-DCBC1A37818CQ35835143-629E657D-0172-4961-99B2-838401037824Q35889806-F7E830E0-8AC5-4DD3-96E3-4FD7CC6F67E6Q35936002-DB5AAEC2-07BC-42B5-B98D-CDA4FD0FF9CCQ35943659-89FE78FA-F4D3-4253-BB2B-45AA140A08A6Q36009719-5C904ADA-9EB6-468A-A774-FA525C236A4EQ36071760-66FAB9F9-E608-42C4-A181-D3C5BF19B813Q36092923-5D9A1934-D9A9-4125-951A-906ACC4943BEQ36313296-528B124A-0B67-4290-A914-7574992F94BEQ36319941-948E6ABE-FBAB-432C-97D1-A452A0CF306FQ36365581-69AA02F4-AF1D-4350-BB55-0E7B689E7FB2Q36433491-EC86F3A6-7FEA-476A-9BFC-237DE7852034Q36451743-5E609043-43BF-47B9-A3EA-1FA017DC9913Q36545311-16519A73-D2CF-48C3-B212-3C2F0CADCAD5Q36567184-2F03EDFC-E497-4037-BE27-1781A3EEF268
P2860
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Age-specific evaluation of pri ...... ology in a randomized setting.
@en
Age-specific evaluation of pri ...... ology in a randomized setting.
@nl
type
label
Age-specific evaluation of pri ...... ology in a randomized setting.
@en
Age-specific evaluation of pri ...... ology in a randomized setting.
@nl
prefLabel
Age-specific evaluation of pri ...... ology in a randomized setting.
@en
Age-specific evaluation of pri ...... ology in a randomized setting.
@nl
P2093
P2860
P356
P1476
Age-specific evaluation of pri ...... ology in a randomized setting.
@en
P2093
Ahti Anttila
Jussi Tarkkanen
Laura Kotaniemi-Talonen
Maarit Leinonen
Nea Malila
Pekka Laurila
Pekka Nieminen
P2860
P304
P356
10.1093/JNCI/DJP367
P407
P577
2009-11-09T00:00:00Z